Condition: Breast Cancer · Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or docetaxel combined with trastuzumab and pertuzumab, respectively.
This description comes directly from the study's public registry record.
Zhimin Shao, Doctor · 18017312288 · szm@163.com
Yongmei Yin, Doctor · 13951842727 · ym.yin@hotmail.com
Always discuss trial participation with your own doctor first.
| Anhui Provincial Cancer Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Anhui Provincial Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Beijing Tiantan Hospital,Capital Medical University | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Gansu Provincial Cancer Hospital | Lanzhou, Gansu, China | Not Yet Recruiting |
| Gansu Provincial Cancer Hospital | Lanzhou, Gansu, China | Not Yet Recruiting |
| Shantou Central Hospital | Shantou, Guangdong, China | Not Yet Recruiting |
| Affiliated Cancer Hospital of Harbin Medical University | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Huaihe Hospital of Henan University | Kaifeng, Henan, China | Not Yet Recruiting |
| Puyang Oilfield General Hospital | Puyang, Henan, China | Not Yet Recruiting |
| The Third People's Hospital of Zhengzhou | Zhengzhou, Henan, China | Not Yet Recruiting |
| Zhongnan Hospital of Wuhan University | Wuhan, Hubei, China | Not Yet Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07003074